The function and application of nuclear localization protein 1 (nulp1) in the treatment of cardiac hypertrophy

A technology of nuclear localization protein and cardiac fibrosis, which is applied in the field of gene function and application, to achieve the effect of inhibiting cardiac hypertrophy, protecting cardiac function, and resisting cardiac fibrosis and cardiac hypertrophy

Active Publication Date: 2017-01-18
WUHAN UNIV
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there are still few related studies on Nulp1. In 2006, Cai ZY et al. found that Nulp1 can act as a transcriptional repressor to inhibit the transcriptional activity of serum response factor (SRF) through the luciferase reporter gene. The DUF654 domain, not the HLH domain, is in it play an important role[20]

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • The function and application of nuclear localization protein 1 (nulp1) in the treatment of cardiac hypertrophy
  • The function and application of nuclear localization protein 1 (nulp1) in the treatment of cardiac hypertrophy
  • The function and application of nuclear localization protein 1 (nulp1) in the treatment of cardiac hypertrophy

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0079] Example 1 Expression of Nulp1 in the hearts of normal people and patients with cardiomyopathy

[0080] SDS-PAGE-Western blot test (Western blot) was performed on proteins extracted from the hearts of normal human hearts (individuals donated by non-cardiac causes of death) and hearts of patients with dilated cardiomyopathy (recipients replaced by patients undergoing heart transplantation, DCM). ), combined with antibodies that specifically recognize Nulp1 protein and cardiomyocyte hypertrophy markers ANP (Millipore, AB2232), β-MHC (santa cruz, sc53090) for detection, and determined the expression of Nulp1 (BETHYL, A303-087A), GAPDH ( Cell Signaling Technology, 2128) as an internal reference. Test results such as figure 1 As shown, the expression of cardiomyocyte hypertrophy markers ANP and β-MHC in the hearts of patients with dilated cardiomyopathy (dilated heart disease) was significantly up-regulated, and the expression of Nulp1 was significantly down-regulated ( fig...

Embodiment 2

[0081] Example 2 Expression of Nulp1 in the heart of wild-type mouse sham operation group and cardiac hypertrophy model group

[0082] 1. Aortic arch constriction (AB) was used to establish a mouse model of myocardial hypertrophy. The model operation process:

[0083] 1.1 Preoperative preparation

[0084] (1) Anesthesia: First weigh the mice, calculate the required amount of anesthetic (3% pentobarbital sodium) according to 90 mg / kg body weight, inject intraperitoneally, and record the injection time point. There is no obvious reaction between tail and toe pinching and the mouse is in good condition. This is the standard for successful anesthesia (generally there is no obvious reaction about 10 minutes after injection, and the mouse has a reaction to pinch toe about 50 minutes after anesthesia, and about 30 minutes after anesthesia is the best operation time).

[0085] (2) Preparation of the operation area: the skin of the left chest, left chest and armpit of the left forelim...

Embodiment 3

[0096] Example 3 Expression of Nulp1 in cardiomyocytes stimulated by control group (PBS) or angiotensin II (Ang II) or phenylephrine (PE)

[0097] Isolate and culture newborn 1-day Sprague-Dawley neonatal rat cardiomyocytes, culture the primary cardiomyocytes for 48 hours and change the medium (see the following example 4 for the specific process of primary neonatal SD rat cardiomyocyte culture), add serum-free DMEM / F12 Starve the cardiomyocytes for 12 hours to synchronize the cells, give PBS, angiotensin II (Ang II, 1 μM) and phenylephrine (PE, 1 μM) stimulation for 48 hours respectively, and perform SDS-PAGE-immunoblotting test on the proteins extracted from cardiomyocytes (Western blot), combined with antibodies that specifically recognize Nulp1 protein and cardiomyocyte hypertrophy markers ANP and β-MHC, were used to detect the expression of Nulp1, and GAPDH was used as an internal reference. Test results such as image 3 As shown, the expressions of ANP and β-MHC in card...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a function and an application of a Nulp1 (Nuclear localized protein-1) in treatment of myocardial hypertrophy and belongs to the field of genetic functions and applications. The correlation between Nulp1 expression and myocardial hypertrophy is determined, research results show that Nulp1 expression is reduced remarkably compared with a normal group in a model with myocardial hypertrophy; myocardial hypertrophy and fibrosis are promoted remarkably and cardiac functions are deteriorated when the Nulp1 expression is inhibited, and myocardial hypertrophy and fibrosis are inhibited remarkably and the cardiac functions are protected when Nulp1 overexpression is promoted. Therefore, the Nulp1 can be taken as a target gene, is used for screening drugs for protecting the cardiac functions, resisting cardiac fibrosis and / or preventing, relieving and / or treating myocardial hypertrophy and is used for preparing drugs for protecting the cardiac functions, resisting myocardial hypertrophy and / or preventing, relieving and / or treating myocardial hypertrophy, and a new effective way for treatment of myocardial hypertrophy is provided.

Description

technical field [0001] The invention belongs to the field of gene function and application, in particular to the function and application of a nuclear localization protein 1 (Nulp1) in the treatment of cardiac hypertrophy. Background technique [0002] Myocardial hypertrophy is the compensatory response of the myocardium to long-term biomechanical pressure or increased volume load, which is commonly seen in cardiovascular diseases such as hypertension and aortic stenosis. Increased and other characteristics [1-3]. Hypertension and senile degenerative aortic valve disease are on the rise year by year in our country. Cardiac hypertrophy and the incidence of hypertension and heart disease caused by hypertension and other diseases also increase thereupon. Although myocardial hypertrophy can initially increase myocardial cells and strengthen myocardial contractility, which is a compensatory mechanism to maintain normal cardiac output, long-term continuous pressure or volume ove...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/68A61K38/17A61K45/00A61P9/00A61P9/04
CPCA61K38/00A61K45/00G01N33/6893G01N2333/47G01N2800/32
Inventor 李红良王丕晓张晓晶
Owner WUHAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap